Exploration of Treatment Strategies with Integrated Traditional Chinese and Western Medicine for Crohn's Disease under the Background of Biological Agents
-
摘要: 克罗恩病(Crohn' s disease, CD)作为慢性、进行性和致残性疾病, 严重影响患者生活质量。近年来随着生物制剂在国内的陆续上市, CD治疗已进入到了生物制剂时代, 治疗目标的不断升级，给临床诊疗带来了诸多挑战。中西医结合治疗可为CD患者提供优化的治疗手段，在生物制剂背景下如何发挥中西医结合治疗的特色和优势是值得关注的临床问题。笔者对生物制剂背景下CD中西医结合治疗策略进行阐述, 临床根据CD不同临床表现，中医可分别以“从痢”“从疡”“从痈”“从络”“从劳”的角度论治；从防治感染、抗纤维化、减少并发症、改善营养不良和促进透壁愈合等方面发挥中西医结合用药的特色优势, 以适应治疗目标的转变, 提高临床疗效。Abstract: Crohn' s disease (CD) is a chronic, progressive and disabling disease, which seriously affects the quality of life of patients. In recent years, with the continuous listing of biological agents in China, the treatment of CD has entered the era of biological agents, which has brought about continuous upgrading of treatment goals and changes in treatment strategies. Integrated traditional Chinese and western medicine has provided optimized treatment methods for CD patients, so how to make use of the advantages of integrated traditional Chinese and western medicine in the background of biological agents is a importent clinical issue. This article elaborates the treatment strategy for CD under the background of biological agents. Clinically, according to the different clinical manifestations of CD, it can be treated from different perspectives of "Li", "Yang", "Yong", "Luo" and "Lao", from the prevention and treatment of infection, anti-fibrosis, reduction of complications, and improvement of malnutrition In order to adapt to the change of treatment goals and improve clinical efficacy.
-
[1] NG SC, SHI HY, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0 [2] ZHAO J, NG SC, LEI Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China[J]. Inflamm Bowel Dis, 2013: 1. [3] ZENG ZR, ZHU ZH, YANG YY, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study[J]. J Gastroenterol Hepatol, 2013, 28(7): 1148-1153. doi: 10.1111/jgh.12164 [4] YANG H, LI YM, WU W, et al. The incidence of inflammatory bowel disease in Northern China: A prospective population-based study[J]. PLoS One, 2014, 9(7): e101296. doi: 10.1371/journal.pone.0101296 [5] PEYRIN-BIROULET L, SANDBORN W, SANDS BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target[J]. Am J Gastroenterol, 2015, 110(9): 1324-1338. doi: 10.1038/ajg.2015.233 [6] PEDERSEN J. Inflammatory pathways of importance for management of inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20(1): 64. doi: 10.3748/wjg.v20.i1.64 [7] MARAFINI I, SEDDA S, DINALLO V, et al. Inflammatory cytokines: From discoveries to therapies in IBD[J]. Expert Opin Biol Ther, 2019, 19: 1207-1217. doi: 10.1080/14712598.2019.1652267 [8] TORRES J, BONOVAS S, DOHERTY G, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment[J]. J Crohn's Colitis, 2020, 14(1): 4-22. doi: 10.1093/ecco-jcc/jjz180 [9] TURNER D, RICCIUTO A, LEWIS A, et al. STRIDE-Ⅱ: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031 [10] YANG E, PANACCIONE N, WHITMIRE N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease[J]. Aliment Pharmacol Ther, 2020, 51(11): 1031-1038. [11] PRIVITERA G, ONALI S, PUGLIESE D, et al. Dual targeted therapy: A possible option for the management of refractory inflammatory bowel disease[J]. J Crohn's Colitis, 2021, 15(2): 335-339. doi: 10.1093/ecco-jcc/jjaa149 [12] CASTIGLIONE F, IMPERATORE N, TESTA A, et al. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing[J]. Aliment Pharmacol Ther, 2019, 49(8): 1026-1039. -
点击查看大图
计量
- 文章访问数: 124
- HTML全文浏览量: 42
- PDF下载量: 15
- 被引次数: 0
下载:
